Molecular Formula | C20H13FN4O2 |
Molar Mass | 360.34 |
Density | 1.354±0.06 g/cm3(Predicted) |
Boling Point | 583.1±50.0 °C(Predicted) |
Solubility | DMSO: >10mg/mL |
Appearance | solid |
Color | light orange |
pKa | 9.09±0.10(Predicted) |
Storage Condition | 2-8°C |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R37/38 - Irritating to respiratory system and skin. R41 - Risk of serious damage to eyes |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye / face protection. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.775 ml | 13.876 ml | 27.752 ml |
5 mM | 0.555 ml | 2.775 ml | 5.55 ml |
10 mM | 0.278 ml | 1.388 ml | 2.775 ml |
5 mM | 0.056 ml | 0.278 ml | 0.555 ml |
biological activity | PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, the IC50 value was 89 nM. PD169316 can eliminate TGFbeta and Activin A- induced signaling. PD169316 has antiviral activity against enterovir71. |
Target | Value |
TGF-β () | |
Activin A () | |
Enterovirus71 () | |
p38 MAPK (Cell-free assay) | 89 nM |
Cell Line: | Ishikawa PRB or PRA cells. |
Concentration: | 10 μM. |
Incubation Time: | 30 min. |
Result: | Did not inhibit MEKK1-induced p38 phosphorylation. Showed antiviral activity. |
Animal Model: | EV71-challenged suckling mouse model (7-day-old Kunming mice). |
Dosage: | 1 mg/kg. |
Administration: | Intramuscular injection every day for 14 consecutive days. |